1. Show article details.

    BRIEF-Baxter International Says Got 510(K) Clearance From U.S. FDA For New Generation Of Its Peri-Strips Dry With Veritas Collagen Matrix Product

    Reuters – 7:37 AM ET 02/27/2020

    Baxter International Inc (BAX): * SAYS GOT 510 CLEARANCE FROM U.S. FDA FOR NEW GENERATION OF ITS PERI-STRIPS DRY WITH VERITAS COLLAGEN MATRIX PRODUCT Source text for Eikon: Further company coverage:

  2. Show article details.

    Baxter Launches Peri-Strips Dry With Secure Grip Technology for Reliable Staple Line Reinforcement in Surgical Procedures

    Business Wire – 7:00 AM ET 02/27/2020

    DEERFIELD, Ill. This press release features multimedia. “We continue to advance innovation by providing surgeons tools that are faster and easier to use in the operating room,” said Wil Boren, president of Baxter’s Advanced Surgery business.

  3. Show article details.

    Baxter to Present at the Raymond James 41st Annual Institutional Investors Conference

    Business Wire – 4:15 PM ET 02/19/2020

    Baxter International Inc. (BAX), a leading global medical products company, will present at the Raymond James 41st Annual Institutional Investors Conference in Orlando, Fla. on Monday, March 2, 2020. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through April 1, 2020.

  4. Show article details.

    Baxter Declares Quarterly Dividend

    Business Wire – 8:00 AM ET 02/18/2020

    Baxter International Inc. (BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per share of common stock. About Baxter Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products.

  5. Show article details.

    Baxter Completes Acquisition of Seprafilm Adhesion Barrier

    Business Wire – 7:00 AM ET 02/18/2020

    Baxter International Inc. (BAX), a leading global medical products company, has completed its previously announced acquisition of Seprafilm Adhesion Barrier and related assets from Sanofi for $350 million.

  6. Show article details.

    BRIEF-Baxter International Says Financial Statements As Of Dec 31, 2018 & 2017, For Yrs Ended Dec 31, 2018, 2017 & 2016, Should No Longer Be Relied Upon

    Reuters – 6:00 PM ET 02/13/2020

    Baxter International Inc (BAX): * BAXTER INTERNATIONAL (BAX) - FINANCIAL STATEMENTS AS OF DEC 31, 2018 & 2017, FOR YRS ENDED DEC 31, 2018, 2017 & 2016, SHOULD NO LONGER BE RELIED UPON. * BAXTER - BELIEVES USE OF PREVIOUS EXCHANGE RATE CONVENTION TO GENERATE NON-OPERATING FOREX GAINS & AVOID LOSSES HAD OCCURRED FOR AT LEAST 10 YRS.

  7. Show article details.

    BRIEF-Baxter And Cosmed Announce U.S. FDA 510(K) Clearance Of Q-Nrg+ Indirect Calorimetry Device

    Reuters – 8:39 AM ET 02/12/2020

    Baxter International Inc (BAX): * BAXTER AND COSMED ANNOUNCE U.S. FDA 510 CLEARANCE OF Q-NRG+ INDIRECT CALORIMETRY DEVICE. * BAXTER INTERNATIONAL (BAX) - Q-NRG+ INDIRECT CALORIMETRY DEVICE EXPECTED TO LAUNCH IN UNITED STATES AT ASPEN CONFERENCE IN MARCH 2020 Source text for Eikon: Further company coverage:

  8. Show article details.

    Baxter and COSMED Announce U.S. FDA 510(k) Clearance of Q-NRG+ Indirect Calorimetry Device

    Business Wire – 8:07 AM ET 02/12/2020

    DEERFIELD, Ill. As part of its partnership with COSMED, Baxter has rights to bring Q-NRG+ to at least 18 markets around the globe, with the potential for further expansion. Hospital malnutrition is a serious public health issue in the United States. Traditional methods of estimating caloric requirements use predictive equations that are based on factors like weight, height, gender and age.

  9. Show article details.

    BRIEF-Baxter And Spectral Medical Announce Exclusive Distribution Agreement For Blood Filter In U.S. And Canada

    Reuters – 7:10 AM ET 02/04/2020

    Baxter International Inc (BAX): * BAXTER AND SPECTRAL MEDICAL ANNOUNCE EXCLUSIVE DISTRIBUTION AGREEMENT FOR BLOOD FILTER IN U.S. AND CANADA Source text for Eikon: Further company coverage:

  10. Show article details.

    Baxter and Spectral Medical Announce Exclusive Distribution Agreement for Blood Filter in U.S. and Canada

    Business Wire – 7:00 AM ET 02/04/2020

    DEERFIELD, Ill. As part of the agreement, Baxter has agreed to pay Spectral a series of milestone payments including a US$5 million upfront rights payment. ”Spectral believes that Baxter is the best industry partner to commercialize the PMX product within the U.S. and Canada,” said Dr. Paul Walker, CEO of Spectral.

  11. Show article details.

    BAXTER 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Baxter International Inc. - BAX

    Business Wire – 10:50 PM ET 01/20/2020

    Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have only until January 24, 2020 to file lead plaintiff applications in a securities class action lawsuit against Baxter International Inc. (BAX), if they purchased the Company’s shares between February 21, 2019, and October 23, 2019, inclusive. What You May Do.

  12. Show article details.

    Baxter to Present at the 9th Annual SVB Leerink Global Healthcare Conference

    Business Wire – 4:15 PM ET 01/15/2020

    Baxter International Inc. (BAX), a leading global medical products company, will present at the 9th Annual SVB Leerink Global Healthcare Conference in New York, N.Y. on Wednesday, February 26, 2020. The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through May 26, 2020.

  13. Show article details.

    BRIEF-Baxter Announces Preliminary Net Sales For The Fourth-Quarter And Full-Year 2019 And Announces Preliminary Full-Year 2020 Guidance

    Reuters – 6:07 PM ET 01/12/2020

    Baxter International Inc (BAX): * BAXTER ANNOUNCES PRELIMINARY NET SALES FOR THE FOURTH-QUARTER AND FULL-YEAR 2019 AND ANNOUNCES PRELIMINARY FULL-YEAR 2020 GUIDANCE. * Q4 SALES $3.0 BILLION VERSUS REFINITIV IBES ESTIMATE OF $2.94 BILLION. * EXPECTS NET SALES GROWTH OF 4% TO 5% ON BOTH A REPORTED AND CONSTANT CURRENCY BASIS FOR FULL YEAR 2020 Source text for Eikon: Further company coverage:

  14. Show article details.

    Baxter Announces Preliminary Net Sales for the Fourth-Quarter and Full-Year 2019 and Announces Preliminary Full-Year 2020 Guidance

    Business Wire – 5:00 PM ET 01/12/2020

    DEERFIELD, Ill. “Our fourth quarter reflects Baxter’s strongest operational sales growth since the 2015 spin-off of Baxalta, driven by outstanding performance across all our global businesses and regions,” said José E. Almeida, chairman and chief executive officer.

  15. Show article details.

    BRIEF-Baxter International Says Co Entered Into A $2 Billion, Five-Year Revolving Credit Agreement

    Reuters – 5:11 PM ET 12/20/2019

    Baxter International Inc (BAX): * BAXTER INTERNATIONAL (BAX) - ENTERED INTO A $2.0 BILLION, FIVE-YEAR REVOLVING CREDIT AGREEMENT. * BAXTER INTERNATIONAL (BAX) - MAY SEEK TO INCREASE AGGREGATE COMMITMENT UNDER CREDIT AGREEMENT BY UP TO $1.0 BILLION WITH MAXIMUM COMMITMENT OF UP TO $3.0 BILLION.

  16. Baxter downgraded to equal weight at Morgan Stanley

    MarketWatch – 9:52 AM ET 12/17/2019
  17. Show article details.

    Baxter to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Business Wire – 4:15 PM ET 12/04/2019

    Baxter International Inc. (BAX), a leading global medical products company, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The live webcast of Baxter’s presentation, along with accompanying slides, can be accessed at www.baxter.com and will be available for replay through July 11, 2020.

  18. Show article details.

    ROSEN, A HIGHLY RANKED FIRM, Announces Filing of Securities Class Action Lawsuit Against Baxter International Inc. - BAX

    PR Newswire – 7:55 PM ET 12/02/2019

    NEW YORK, Dec. 2, 2019  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Baxter International Inc. (BAX) between February 21, 2019 and October 23, 2019, inclusive.

  19. Show article details.

    Sanofi agrees to sell Seprafilm to Baxter for $350 mln

    Reuters – 7:42 AM ET 12/02/2019

    Medical supply company Baxter International Inc (BAX) said on Monday it had agreed to buy Sanofi's Seprafilm unit, which makes specialist surgical products, for $350 million in cash. The deal should close by the end of the first quarter of 2020, Baxter added in a statement confirming the purchase, which was reported earlier by Reuters.

  20. Show article details.

    BRIEF-Baxter To Expand Advanced Surgery Portfolio With Acquisition Of Seprafilm Adhesion Barrier

    Reuters – 7:31 AM ET 12/02/2019

    Baxter International Inc (BAX): * BAXTER TO EXPAND ADVANCED SURGERY PORTFOLIO WITH ACQUISITION OF SEPRAFILM ADHESION BARRIER. * Baxter International Inc (BAX) - TRANSACTION CONTEMPLATES A CASH PURCHASE PRICE AT CLOSING OF $350 MILLION. * Baxter International Inc (BAX) - SALES OF PROPOSED ACQUIRED PRODUCTS ARE EXPECTED TO BE APPROXIMATELY $100 MILLION IN 12 MONTHS FOLLOWING CLOSE.

Page:

Today's and Upcoming Events

  • Feb
    28

    BAX to announce Q4 earnings (Unconfirmed)

Past Events (last 90 days)

  • Feb
    27

    BAX ex-Dividend for $0.22 on 02/27/2020

    • Announce Date: 02/18/2020
    • Record Date: 02/28/2020
    • Pay Date: 04/01/2020
  • Dec
    05

    BAX ex-Dividend for $0.22 on 12/05/2019

    • Announce Date: 11/19/2019
    • Record Date: 12/06/2019
    • Pay Date: 01/02/2020
Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.